{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:11:37Z","timestamp":1778695897414,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,13]]},"DOI":"10.7759\/cureus.108793","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:12:41Z","timestamp":1778692361000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Treatment After Liver Transplantation: A Hypothesis-Generating Case Report"],"prefix":"10.7759","author":[{"given":"Nonka N","family":"Yurukova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bissima","family":"Sultani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song Q","year":"2023","unstructured":"Song Q, Zhang X, Liu W, et al.. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023, 79:1352-65. 10.1016\/j.jhep.2023.07.005","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton M","year":"2018","unstructured":"Charlton M, Levitsky J, Aqel B, et al.. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018, 102:727-43. 10.1097\/TP.0000000000002147","journal-title":"Transplantation"},{"key":"ref3","article-title":"Tacrolimus (Prograf) Prescribing Information, U.S. Food and Drug Administration","author":"DailyMed","year":"2025","unstructured":"DailyMed. Tacrolimus (Prograf) Prescribing Information, U.S. Food and Drug Administration. DailyMed, Bethesda, MD; 2025."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002750","article-title":"Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation","volume":"103","author":"Lu\u00e9 A","year":"2019","unstructured":"Lu\u00e9 A, Martinez E, Navarro M, et al.. Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation. Transplantation. 2019, 103:e211-5. 10.1097\/TP.0000000000002750","journal-title":"Transplantation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01398-5","article-title":"Tacrolimus-induced neurotoxicity after transplant: a literature review","volume":"47","author":"Verona P","year":"2024","unstructured":"Verona P, Edwards J, Hubert K, et al.. Tacrolimus-induced neurotoxicity after transplant: a literature review. Drug Saf. 2024, 47:419-38. 10.1007\/s40264-024-01398-5","journal-title":"Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate JE","year":"2015","unstructured":"Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015, 14:914-25. 10.1016\/S1474-4422(15)00111-8","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00232-7","article-title":"Posterior reversible encephalopathy syndrome: evolving insights in diagnosis, management, and outcomes","volume":"24","author":"Fugate JE","year":"2025","unstructured":"Fugate JE, Hawkes MA, Rabinstein AA. Posterior reversible encephalopathy syndrome: evolving insights in diagnosis, management, and outcomes. Lancet Neurol. 2025, 24:789-800. 10.1016\/S1474-4422(25)00232-7","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(84)91556-3","article-title":"Association between cyclosporin neurotoxicity and hypomagnesaemia","volume":"2","author":"Thompson CB","year":"1984","unstructured":"Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984, 2:1116-20. 10.1016\/s0140-6736(84)91556-3","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al.. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab. 2024, 110:1-15. 10.1210\/clinem\/dgae719","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002820","article-title":"Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management","volume":"119","author":"Hiramoto B","year":"2024","unstructured":"Hiramoto B, McCarty TR, Lodhia NA, et al.. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am J Gastroenterol. 2024, 119:1126-40. 10.14309\/ajg.0000000000002820","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong MJ","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016, 387:679-90. 10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026, 49:S183-215. 10.2337\/dc26-S009","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134619","article-title":"Efficacy and safety of GLP-1 receptor agonists and SGLT-2 inhibitors in the treatment of diabetes mellitus and obesity in liver transplant recipients: a systematic review","volume":"14","author":"Garlatti Costa E","year":"2025","unstructured":"Garlatti Costa E, Bitetto D, Fornasiere E, Fumolo E, Ferrarese A, Toniutto P. Efficacy and safety of GLP-1 receptor agonists and SGLT-2 inhibitors in the treatment of diabetes mellitus and obesity in liver transplant recipients: a systematic review. J Clin Med. 2025, 14:4619. 10.3390\/jcm14134619","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1586941","article-title":"Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors","volume":"16","author":"Grancini V","year":"2025","unstructured":"Grancini V, Cogliati I, Alicandro G, et al.. Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors. Front Endocrinol (Lausanne). 2025, 16:1586941. 10.3389\/fendo.2025.1586941","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15769","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients","volume":"26","author":"Zheng K","year":"2024","unstructured":"Zheng K, Azhie A, You X, et al.. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients. Diabetes Obes Metab. 2024, 26:4261-72. 10.1111\/dom.15769","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801209","article-title":"Hyponatremia and mortality in patients on the liver transplant waiting list","volume":"359","author":"Kim WR","year":"2008","unstructured":"Kim WR, Biggins SW, Kremers WK, et al.. Hyponatremia and mortality in patients on the liver transplant waiting list. N Engl J Med. 2008, 359:1018-26. 10.1056\/NEJMoa0801209","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13619","article-title":"Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients","volume":"21","author":"Singh P","year":"2019","unstructured":"Singh P, Pesavento TE, Washburn K, Walsh D, Meng S. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. Diabetes Obes Metab. 2019, 21:1061-5. 10.1111\/dom.13619","journal-title":"Diabetes Obes Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510603","article-title":"Magnesium disorders","volume":"390","author":"Touyz RM","year":"2024","unstructured":"Touyz RM, de Baaij JH, Hoenderop JG. Magnesium disorders. N Engl J Med. 2024, 390:1998-2009. 10.1056\/NEJMra1510603","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0531-7","article-title":"No dose adjustment is recommended for digoxin, warfarin, atorvastatin or a combination oral contraceptive when coadministered with dulaglutide","volume":"56","author":"de la Pe\u00f1a A","year":"2017","unstructured":"de la Pe\u00f1a A, Cui X, Geiser J, Loghin C. No dose adjustment is recommended for digoxin, warfarin, atorvastatin or a combination oral contraceptive when coadministered with dulaglutide. Clin Pharmacokinet. 2017, 56:1415-27. 10.1007\/s40262-017-0531-7","journal-title":"Clin Pharmacokinet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70007","article-title":"GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis","volume":"45","author":"Hooper L","year":"2025","unstructured":"Hooper L, Liu S, Pai MP. GLP-1RA-induced delays in gastrointestinal motility: predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy. 2025, 45:211-9. 10.1002\/phar.70007","journal-title":"Pharmacotherapy"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky B","year":"2024","unstructured":"Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. Drug Saf. 2024, 47:439-51. 10.1007\/s40264-023-01392-3","journal-title":"Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup H","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al.. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014, 60:715-35. 10.1002\/hep.27210","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s P","year":"2021","unstructured":"Gin\u00e8s P, Krag A, Abraldes JG, et al.. Liver cirrhosis. Lancet. 2021, 398:1359-76. 10.1016\/S0140-6736(21)01374-X","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318196340d","article-title":"Postshunt hepatic encephalopathy in liver transplant recipients","volume":"87","author":"Braun MM","year":"2009","unstructured":"Braun MM, Bar-Nathan N, Shaharabani E, et al.. Postshunt hepatic encephalopathy in liver transplant recipients. Transplantation. 2009, 87:734-9. 10.1097\/TP.0b013e318196340d","journal-title":"Transplantation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26298","article-title":"Hepatic encephalopathy in a liver transplant recipient with stable liver function","volume":"57","author":"Arab JP","year":"2013","unstructured":"Arab JP, Meneses L, P\u00e9rez RM, Arrese M, Ben\u00edtez C. Hepatic encephalopathy in a liver transplant recipient with stable liver function. Hepatology. 2013, 57:1672-4. 10.1002\/hep.26298","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464607-glucagon-like-peptide-1-glp-1-receptor-agonist-treatment-after-liver-transplantation-a-hypothesis-generating-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:12:42Z","timestamp":1778692362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464607-glucagon-like-peptide-1-glp-1-receptor-agonist-treatment-after-liver-transplantation-a-hypothesis-generating-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.108793","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}